NX Prenatal, NxGEN MDx Announce Partnership
Complete the form below to unlock access to ALL audio articles.
NX Prenatal Inc. has announced a strategic partnership with NxGEN MDx, LLC to collaborate on the development and commercial deployment of its blood tests to assess early pregnancy biomarkers of preterm birth risk. The partnership brings together NX Prenatal's experience in developing exosome-associated biomarkers from maternal blood with NxGEN MDx's rapidly growing reputation as a best-in-class provider of testing solutions focused on women's health.
Preterm birth affects up to 1 in 8 U.S. pregnancies, with nearly half a million preterm births each year. These preterm births represent an annual cost to the system of approximately $26 billion. Globally, there are approximately 15 million preterm births each year which account for 75% of perinatal deaths and are a major determinant of short and long term morbidity in infants and children.
"We are excited to partner with the innovative NX Prenatal team. Our combined efforts are designed to fulfill the industry's stated goal of early identification of which pregnant women are at increased risk for delivering prematurely, and NX Prenatal has demonstrated that its technology uniquely holds the potential to achieve this breakthrough," said Alan Mack, CEO of NxGEN MDx. "This new generation of diagnostics is complementary to our current suite of tests which help families and their physicians plan for healthy pregnancy outcomes," noted Mack.
"In addition to helping clinicians proactively manage those at greatest risk, patients and families will benefit from personalized care and potential tailored interventions, while payers and self-insured employers may ultimately experience lower claims costs related to preterm birth as well as a healthier population base," notes Gail Page, Executive Chair of NX Prenatal.
